206 related articles for article (PubMed ID: 35456633)
1. Mucoadhesive PLGA Nanospheres and Nanocapsules for Lactoferrin Controlled Ocular Delivery.
Varela-Fernández R; García-Otero X; Díaz-Tomé V; Regueiro U; López-López M; González-Barcia M; Isabel Lema M; Otero-Espinar FJ
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456633
[TBL] [Abstract][Full Text] [Related]
2. Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan/TPP and Chitosan/Sulfobutylether-β-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment.
Varela-Fernández R; García-Otero X; Díaz-Tomé V; Regueiro U; López-López M; González-Barcia M; Lema MI; Otero-Espinar FJ
ACS Appl Mater Interfaces; 2021 Jan; 13(3):3559-3575. PubMed ID: 33428398
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
4. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery.
Varela-Fernández R; García-Otero X; Díaz-Tomé V; Regueiro U; López-López M; González-Barcia M; Isabel Lema M; Javier Otero-Espinar F
Eur J Pharm Biopharm; 2022 Mar; 172():144-156. PubMed ID: 35183717
[TBL] [Abstract][Full Text] [Related]
5. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
6. Development of topical eye-drops of lactoferrin-loaded biodegradable nanoparticles for the treatment of anterior segment inflammatory processes.
López-Machado A; Díaz N; Cano A; Espina M; Badía J; Baldomà L; Calpena AC; Biancardi M; Souto EB; García ML; Sánchez-López E
Int J Pharm; 2021 Nov; 609():121188. PubMed ID: 34655707
[TBL] [Abstract][Full Text] [Related]
7. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
8. Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies.
Lalani J; Rathi M; Lalan M; Misra A
Drug Dev Ind Pharm; 2013 Jun; 39(6):854-64. PubMed ID: 22799442
[TBL] [Abstract][Full Text] [Related]
9. Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment.
Esteruelas G; Halbaut L; García-Torra V; Espina M; Cano A; Ettcheto M; Camins A; Souto EB; Luisa García M; Sánchez-López E
Int J Pharm; 2022 Jan; 612():121379. PubMed ID: 34915146
[TBL] [Abstract][Full Text] [Related]
10. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC; Chen YC
Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309
[TBL] [Abstract][Full Text] [Related]
11. Lipid-PLGA hybrid nanoparticles of paclitaxel: Preparation, characterization, in vitro and in vivo evaluation.
Godara S; Lather V; Kirthanashri SV; Awasthi R; Pandita D
Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110576. PubMed ID: 32228957
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
13. PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers.
Jiang G; Jia H; Qiu J; Mo Z; Wen Y; Zhang Y; Wen Y; Xie Q; Ban J; Lu Z; Chen Y; Wu H; Ni Q; Chen F; Lu J; Wang Z; Li H; Chen J
Int J Nanomedicine; 2020; 15():9373-9387. PubMed ID: 33262593
[TBL] [Abstract][Full Text] [Related]
14. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
Nanomedicine; 2010 Apr; 6(2):324-33. PubMed ID: 19857606
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles.
Tahara K; Karasawa K; Onodera R; Takeuchi H
Asian J Pharm Sci; 2017 Jul; 12(4):394-399. PubMed ID: 32104351
[TBL] [Abstract][Full Text] [Related]
16. Cell penetrating peptides-functionalized Licochalcone-A-loaded PLGA nanoparticles for ocular inflammatory diseases: Evaluation of in vitro anti-proliferative effects, stabilization by freeze-drying and characterization of an in-situ forming gel.
Galindo-Camacho RM; Haro I; Gómara MJ; Espina M; Fonseca J; Martins-Gomes C; Camins A; Silva AM; García ML; Souto EB
Int J Pharm; 2023 May; 639():122982. PubMed ID: 37116598
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone.
Teixeira M; Alonso MJ; Pinto MM; Barbosa CM
Eur J Pharm Biopharm; 2005 Apr; 59(3):491-500. PubMed ID: 15760730
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors.
d'Angelo I; Garcia-Fuentes M; Parajó Y; Welle A; Vántus T; Horváth A; Bökönyi G; Kéri G; Alonso MJ
Mol Pharm; 2010 Oct; 7(5):1724-33. PubMed ID: 20681555
[TBL] [Abstract][Full Text] [Related]
19. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
20. Development, Optimization, and Clinical Relevance of Lactoferrin Delivery Systems: A Focus on Ocular Delivery.
Ponzini E; Astolfi G; Grandori R; Tavazzi S; Versura P
Pharmaceutics; 2024 Jun; 16(6):. PubMed ID: 38931931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
